Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Identifieur interne : 001792 ( Main/Merge ); précédent : 001791; suivant : 001793Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
Auteurs : Christopher M. Coleman [États-Unis] ; Ye V. Liu [États-Unis] ; HAIYAN MU [États-Unis] ; Justin K. Taylor [États-Unis] ; Michael Massare [États-Unis] ; David C. Flyer [États-Unis] ; Gregory M. Glenn [États-Unis] ; Gale E. Smith [États-Unis] ; Matthew B. Frieman [États-Unis]Source :
- Vaccine [ 0264-410X ] ; 2014.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Vaccin.
English descriptors
- KwdEn :
Abstract
Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: 000006
- to stream PascalFrancis, to step Curation: 000981
- to stream PascalFrancis, to step Checkpoint: 000005
Links to Exploration step
Pascal:14-0134129Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author><author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">INIST</idno><idno type="inist">14-0134129</idno><date when="2014">2014</date><idno type="stanalyst">PASCAL 14-0134129 INIST</idno><idno type="RBID">Pascal:14-0134129</idno><idno type="wicri:Area/PascalFrancis/Corpus">000006</idno><idno type="wicri:Area/PascalFrancis/Curation">000981</idno><idno type="wicri:Area/PascalFrancis/Checkpoint">000005</idno><idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000005</idno><idno type="wicri:doubleKey">0264-410X:2014:Coleman C:purified:coronavirus:spike</idno><idno type="wicri:Area/Main/Merge">001792</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice</title><author><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author><author><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author><author><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><affiliation wicri:level="2"><inist:fA14 i1="02"><s1>Novavax, Inc. 22 Firstfield Rd</s1><s2>Gaithersburg, MD 20852</s2><s3>USA</s3><sZ>2 aut.</sZ><sZ>3 aut.</sZ><sZ>5 aut.</sZ><sZ>6 aut.</sZ><sZ>7 aut.</sZ><sZ>8 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name><affiliation wicri:level="4"><inist:fA14 i1="01"><s1>University of Maryland, School of Medicine, 685 West Baltimore St</s1><s2>Baltimore, MD 21201</s2><s3>USA</s3><sZ>1 aut.</sZ><sZ>4 aut.</sZ><sZ>9 aut.</sZ></inist:fA14><country>États-Unis</country><placeName><region type="state">Maryland</region><settlement type="city">College Park (Maryland)</settlement></placeName><orgName type="university">Université du Maryland</orgName></affiliation></author></analytic><series><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno><imprint><date when="2014">2014</date></imprint></series></biblStruct></sourceDesc><seriesStmt><title level="j" type="main">Vaccine</title><title level="j" type="abbreviated">Vaccine</title><idno type="ISSN">0264-410X</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Coronavirus</term><term>Middle east</term><term>Mouse</term><term>Nanoparticle</term><term>Neutralizing antibody</term><term>Protein</term><term>Severe acute respiratory syndrome</term><term>Vaccine</term></keywords><keywords scheme="Pascal" xml:lang="fr"><term>Coronavirus</term><term>Souris</term><term>Protéine</term><term>Nanoparticule</term><term>Anticorps neutralisant</term><term>Moyen Orient</term><term>Vaccin</term><term>Syndrome respiratoire aigu sévère</term></keywords><keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Vaccin</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Development of vaccination strategies for emerging pathogens are particularly challenging because of the sudden nature of their emergence and the long process needed for traditional vaccine development. Therefore, there is a need for development of a rapid method of vaccine development that can respond to emerging pathogens in a short time frame. The emergence of severe acute respiratory syndrome coronavirus (SARS-CoV) in 2003 and Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in late 2012 demonstrate the importance of coronaviruses as emerging pathogens. The spike glycoproteins of coronaviruses reside on the surface of the virion and are responsible for virus entry. The spike glycoprotein is the major immunodominant antigen of coronaviruses and has proven to be an excellent target for vaccine designs that seek to block coronavirus entry and promote antibody targeting of infected cells. Vaccination strategies for coronaviruses have involved live attenuated virus, recombinant viruses, non-replicative virus-like particles expressing coronavirus proteins or DNA plasmids expressing coronavirus genes. None of these strategies has progressed to an approved human coronavirus vaccine in the ten years since SARS-CoV emerged. Here we describe a novel method for generating MERS-CoV and SARS-CoV full-length spike nanoparticles, which in combination with adjuvants are able to produce high titer antibodies in mice.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Maryland</li></region><settlement><li>College Park (Maryland)</li></settlement><orgName><li>Université du Maryland</li></orgName></list><tree><country name="États-Unis"><region name="Maryland"><name sortKey="Coleman, Christopher M" sort="Coleman, Christopher M" uniqKey="Coleman C" first="Christopher M." last="Coleman">Christopher M. Coleman</name></region><name sortKey="Flyer, David C" sort="Flyer, David C" uniqKey="Flyer D" first="David C." last="Flyer">David C. Flyer</name><name sortKey="Frieman, Matthew B" sort="Frieman, Matthew B" uniqKey="Frieman M" first="Matthew B." last="Frieman">Matthew B. Frieman</name><name sortKey="Glenn, Gregory M" sort="Glenn, Gregory M" uniqKey="Glenn G" first="Gregory M." last="Glenn">Gregory M. Glenn</name><name sortKey="Haiyan Mu" sort="Haiyan Mu" uniqKey="Haiyan Mu" last="Haiyan Mu">HAIYAN MU</name><name sortKey="Liu, Ye V" sort="Liu, Ye V" uniqKey="Liu Y" first="Ye V." last="Liu">Ye V. Liu</name><name sortKey="Massare, Michael" sort="Massare, Michael" uniqKey="Massare M" first="Michael" last="Massare">Michael Massare</name><name sortKey="Smith, Gale E" sort="Smith, Gale E" uniqKey="Smith G" first="Gale E." last="Smith">Gale E. Smith</name><name sortKey="Taylor, Justin K" sort="Taylor, Justin K" uniqKey="Taylor J" first="Justin K." last="Taylor">Justin K. Taylor</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Merge
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001792 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Merge/biblio.hfd -nk 001792 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= SrasV1
|flux= Main
|étape= Merge
|type= RBID
|clé= Pascal:14-0134129
|texte= Purified coronavirus spike protein nanoparticles induce coronavirus neutralizing antibodies in mice
}}
| This area was generated with Dilib version V0.6.33. |  |